Susquehanna International Group
VNDA icon

Susquehanna International Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Susquehanna International Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.72M Sell
249,300
-32,800
-12% -$253K ﹤0.01% 6526
2025
Q4 		$2.49M Buy
282,100
+230,200
+444% +$1.27M ﹤0.01% 5207
2025
Q3 		$259K Buy
+51,900
New +$240K ﹤0.01% 10448
2025
Q2 		– Sell
-11,700
Closed -$53.7K – 13796
2025
Q1 		$53.7K Buy
+11,700
New +$54.5K ﹤0.01% 11834
2024
Q4 		– Sell
-13,900
Closed -$65.2K – 13328
2024
Q3 		$65.2K Buy
+13,900
New +$74.5K ﹤0.01% 11274
2024
Q2 		– Sell
-13,600
Closed -$55.9K – 13318
2024
Q1 		$55.9K Buy
+13,600
New +$54.4K ﹤0.01% 11521
2023
Q1 		– Sell
-12,200
Closed -$90.2K – 13565
2022
Q4 		$90.2K Sell
12,200
-33,200
-73% -$323K ﹤0.01% 11049
2022
Q3 		$449K Buy
45,400
+25,200
+125% +$266K ﹤0.01% 8779
2022
Q2 		$220K Sell
20,200
-13,200
-40% -$137K ﹤0.01% 10404
2022
Q1 		$378K Sell
33,400
-220,700
-87% -$2.9M ﹤0.01% 9687
2021
Q4 		$3.99M Buy
254,100
+193,400
+319% +$3.37M ﹤0.01% 4130
2021
Q3 		$1.04M Buy
60,700
+3,000
+5% +$52.5K ﹤0.01% 7455
2021
Q2 		$1.24M Sell
57,700
-41,300
-42% -$739K ﹤0.01% 7150
2021
Q1 		$1.49M Buy
99,000
+65,000
+191% +$1.05M ﹤0.01% 6660
2020
Q4 		$447K Sell
34,000
-24,000
-41% -$289K ﹤0.01% 8526
2020
Q3 		$560K Sell
58,000
-20,700
-26% -$221K ﹤0.01% 7437
2020
Q2 		$900K Buy
78,700
+68,200
+650% +$772K ﹤0.01% 6158
2020
Q1 		$109K Sell
10,500
-22,900
-69% -$284K ﹤0.01% 9261
2019
Q4 		$548K Buy
33,400
+10,800
+48% +$163K ﹤0.01% 6811
2019
Q3 		$300K Sell
22,600
-5,400
-19% -$75.3K ﹤0.01% 8302
2019
Q2 		$395K Buy
28,000
+5,500
+24% +$87.5K ﹤0.01% 7760
2019
Q1 		$414K Buy
22,500
+1,900
+9% +$43.3K ﹤0.01% 6634
2018
Q4 		$538K Buy
20,600
+10,200
+98% +$240K ﹤0.01% 5890
2018
Q3 		$239K Sell
10,400
-7,300
-41% -$149K ﹤0.01% 7909
2018
Q2 		$337K Buy
17,700
+3,700
+26% +$61.9K ﹤0.01% 7613
2018
Q1 		$236K Buy
14,000
+1,200
+9% +$20.1K ﹤0.01% 8042
2017
Q4 		$195K Sell
12,800
-23,400
-65% -$347K ﹤0.01% 8301
2017
Q3 		$648K Buy
36,200
+9,300
+35% +$156K ﹤0.01% 6067
2017
Q2 		$438K Buy
26,900
+6,600
+33% +$95.1K ﹤0.01% 6893
2017
Q1 		$284K Sell
20,300
-36,300
-64% -$517K ﹤0.01% 7425
2016
Q4 		$903K Sell
56,600
-96,200
-63% -$1.55M ﹤0.01% 5745
2016
Q3 		$2.54M Buy
152,800
+88,500
+138% +$1.19M ﹤0.01% 3158
2016
Q2 		$720K Sell
64,300
-23,600
-27% -$229K ﹤0.01% 5485
2016
Q1 		$735K Sell
87,900
-138,300
-61% -$1.14M ﹤0.01% 5698
2015
Q4 		$2.11M Sell
226,200
-84,500
-27% -$843K ﹤0.01% 3931
2015
Q3 		$3.5M Buy
310,700
+83,100
+37% +$1.02M ﹤0.01% 3228
2015
Q2 		$2.89M Sell
227,600
-704,200
-76% -$7.59M ﹤0.01% 3928
2015
Q1 		$8.67M Buy
931,800
+563,600
+153% +$6.37M ﹤0.01% 2018
2014
Q4 		$5.27M Buy
368,200
+98,100
+36% +$1.16M ﹤0.01% 2809
2014
Q3 		$2.8M Sell
270,100
-327,200
-55% -$4.29M ﹤0.01% 4021
2014
Q2 		$9.66M Sell
597,300
-396,200
-40% -$5.28M ﹤0.01% 2153
2014
Q1 		$16.1M Buy
993,500
+598,700
+152% +$8.51M 0.01% 1482
2013
Q4 		$4.9M Sell
394,800
-798,900
-67% -$8.02M ﹤0.01% 2973
2013
Q3 		$13.1M Buy
1,193,700
+604,500
+103% +$6.46M 0.01% 1604
2013
Q2 		$4.76M Buy
+589,200
New +$3.97M ﹤0.01% 2691

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's VNDA Position: Q1 2026 in Review

Susquehanna International Group reduced its Vanda Pharmaceuticals (VNDA) stake by 46% in Q1 2026, selling an estimated $674K and leaving 103,202 shares worth $713K. The position accounts for ﹤0.01% of the portfolio, ranked #8771.

Susquehanna International Group first reported a position in VNDA in Q2 2013 and has held it in 45 quarters since. The position peaked at $3.23M in Q1 2019. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Susquehanna International Group held 103,202 shares of Vanda Pharmaceuticals worth $713K as of Q1 2026.
  • Susquehanna International Group sold 87,420 Vanda Pharmaceuticals shares in Q1 2026, an estimated $674K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8771 holding.
  • Susquehanna International Group first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
  • Susquehanna International Group's Vanda Pharmaceuticals position peaked at $3.23M in Q1 2019.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.